The FDA told Amgen to test whether a quarter-dose of sotorasib worked as well as the amount on the label. It did, but the biotech is sticking to the higher dose, which earns it an extra $180,000 a ...
Just last week, Tesla laid off yet another round of workers. This time, however, Tesla gutted an entire team. Around 500 ...
Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...
The move comes after the Elon Musk-led automaker disbanded its EV charging department following Tesla’s announcement last ...
Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...
Valley Vision releases its first Inclusive Economy Poll. Also, a Sacramento physician pens a debut fiction novel “Dry Spells.
Stocks Rally As Jobs Report Rekindles Rate Cut Hopes, Apple Rockets, Bitcoin Soars Above $61,000: What's Driving Markets Friday? A weaker-than-expected jobs report sparked a widespread market ...
Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion. Bristol Myers Squibb agreed to a ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira. The ...